Piper Jaffray analyst Christopher Raymond kept his Overweight rating and $402 price target on Biogen (BIIB) after the latest filing disclosing that Mylan (MYL) petitioned U.S. PTAB to review its '514 patent covering the treatment of MS with 480 mg of dimethyl fumarate per day as provided for in Biogen's Tecfidera label. The analyst notes that while the worst case scenario could remove about $50 per share from his sum-of-parts analysis on Biogen, he sees it as "unlikely", since the patent has been resilient to two prior challenges which were decided in Biogen's favor.
https://thefly.com/landingPageNews.php?id=2860515
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.